Earnings Misses

Affirm Holdings Selloff Is 'Baffling': Analysts Dive Into Financial Results
Airbnb Stock Plummets As JPMorgan Analyst Praises 'Solid Q1, Stable Q2, Acceleration In Q3'
Stocks Falter As Fed Signals Need For Higher-For-Longer Rates; Uber Crashes, Energy Sector Loses Ground: What's Driving Wednesday's Market?
Airbnb Stock Plummets As JPMorgan Analyst Praises 'Solid Q1, Stable Q2, Acceleration In Q3'
Stocks Falter As Fed Signals Need For Higher-For-Longer Rates; Uber Crashes, Energy Sector Loses Ground: What's Driving Wednesday's Market?
Apyx Medical Reports Q1 Loss, Tops Revenue Estimates
Shopify Profitability Remains A Concern, 5 Analysts Offer Commentary On Q1 Earnings

Earnings Misses Recent News

Lyft Enjoys 'Continued Momentum': 3 Analysts Examine Q1 Earnings, Outlook Ahead Of Investor Day
CBD-Focused Charlotte's Web Revenue Drops 29% In Q1 Amid Strategic Adjustments
Charlotte's Web reports a 29% revenue decline in Q1 2024, faces net loss, and plans strategic adjustments to boost operational efficiency.
Hims & Hers Health's Model 'Proving Effective': 2 Analysts Examine Q1 Earnings
Hims & Hers Health reported total revenue of $278.2 million, a 46% year-on-year growth and higher than Street expectations of $270.4 million.
Symbotic Reports Q1 Beat: Analysts Boost Their 2024 Estimates, 'Strong Secular Growth Story'
Symbotic shares climb on strong Q2 sales beat. Analysts expect continued growth and raised estimates for fiscal 2024. Stock up 9.63%.
Shopify Q1 Preview: Analysts Predict Strong Sales Growth
Truist Securities analyst expects strong GMV growth for Shopify in Q1, with potential upside in subscription and merchant solutions revenue.
Berkshire Hathaway Analyst Raises Forecasts After Q1 Results — But Remains Cautious
Why the Keefe, Bruyette & Woods analyst maintains a Market Perform rating while raising the stock's price target.
BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (NASDAQ: BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics, Inc. (NASDAQ: OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.
Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
Green Plains Renewable Energy Reports Q1 Loss, Misses Revenue Estimates
Green Plains Renewable Energy (NASDAQ: GPRE) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $1.20 per share a year ago. These figures are adjusted for non-recurring items.
Booking Holdings Issues Soft Guidance Despite Strong Q1 Upside; These Analysts Delve Deeper
Block Reports Blockbuster Results, Raises Guidance: Analysts Talk Square, Cash App, More
Block shares up on upbeat Q1 results amid exciting earnings season. Analysts maintain Buy and Outperform ratings with price targets up to $106.
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers